{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,27]],"date-time":"2026-05-27T22:06:04Z","timestamp":1779919564532,"version":"3.53.1"},"reference-count":9,"publisher":"Elsevier BV","issue":"6","license":[{"start":{"date-parts":[[2026,6,1]],"date-time":"2026-06-01T00:00:00Z","timestamp":1780272000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,6,1]],"date-time":"2026-06-01T00:00:00Z","timestamp":1780272000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["European Urology"],"published-print":{"date-parts":[[2026,6]]},"DOI":"10.1016\/j.eururo.2026.01.012","type":"journal-article","created":{"date-parts":[[2026,1,23]],"date-time":"2026-01-23T21:03:57Z","timestamp":1769202237000},"page":"e144-e145","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"title":["Reply to the Harry Herr\u2019s Letter to the Editor re: Oscar Buisan, Pol Servian, Sonia Pedre\u00f1o-Lopez, et al. A Novel Heterologous Prime-boost Strategy Using RUTI Vaccine to Improve the Bacillus Calmette-Gu\u00e9rin Response in Non\u2013muscle-invasive Bladder Cancer Patients: Phase 1 RUTIVAC-1 Trial. Eur Urol. 2026;89:114\u2013120"],"prefix":"10.1016","volume":"89","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-9941-6828","authenticated-orcid":false,"given":"Cecilia","family":"Cabrera","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Oscar","family":"Buisan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pol","family":"Servian","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.eururo.2026.01.012_b0005","doi-asserted-by":"crossref","first-page":"441","DOI":"10.1200\/JCO.1987.5.3.441","article-title":"A prospective randomized trial of maintenance versus nonmaintenance intravesical BCG therapy of superficial bladder cancer","volume":"5","author":"Badalament","year":"1987","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.eururo.2026.01.012_b0010","doi-asserted-by":"crossref","DOI":"10.1126\/scitranslmed.3003586","article-title":"Preexisting BCG-specific T cells improve intravesical immunotherapy for bladder cancer","volume":"4","author":"Biot","year":"2012","journal-title":"Sci Transl Med"},{"key":"10.1016\/j.eururo.2026.01.012_b0015","doi-asserted-by":"crossref","first-page":"131","DOI":"10.1046\/j.1365-2249.1999.00756.x","article-title":"Systemic immune response after intravesical instillation of BCG for superficial bladder cancer","volume":"115","author":"Taniguchi","year":"1999","journal-title":"Clin Exp Immunol"},{"key":"10.1016\/j.eururo.2026.01.012_b0020","doi-asserted-by":"crossref","first-page":"522","DOI":"10.1001\/jamaoncol.2023.6804","article-title":"Response to 2 induction courses of BCG therapy among patients with high-risk non-muscle-invasive bladder cancer. 5-year follow-up of a phase 2 clinical trial","volume":"10","author":"Katims","year":"2024","journal-title":"JAMA Oncol"},{"key":"10.1016\/j.eururo.2026.01.012_b0025","doi-asserted-by":"crossref","first-page":"474","DOI":"10.23736\/S2724-6051.23.05515-5","article-title":"The impact of purified protein derivative prior to intravesical bacillus Calmette-Gu\u00e9rin for the treatment of patients with non-muscle invasive bladder cancer","volume":"76","author":"Zawky","year":"2024","journal-title":"Minerva Urol Nephrol"},{"key":"10.1016\/j.eururo.2026.01.012_b0030","doi-asserted-by":"crossref","first-page":"301","DOI":"10.1007\/s11255-022-03414-y","article-title":"The use of natural killer cell activity and PPD test in the prediction of results in intravesical BCG treatment of patients with nonmuscle-invasive bladder cancer","volume":"55","author":"Yazici","year":"2023","journal-title":"Int Urol Nephrol"},{"key":"10.1016\/j.eururo.2026.01.012_b0035","doi-asserted-by":"crossref","unstructured":"Buisan O, Servian P, Pedre\u00f1o-Lopez S, et al. A novel heterologous prime-boost strategy using RUTI vaccine to improve the bacillus Calmette-Gu\u00e9rin response in non\u2013muscle-invasive bladder cancer patients: phase 1 RUTIVAC-1 trial. Eur Urol. Eur Urol. 2026;89:114\u201320.","DOI":"10.1016\/j.eururo.2025.08.014"},{"key":"10.1016\/j.eururo.2026.01.012_b0040","doi-asserted-by":"crossref","first-page":"1255","DOI":"10.1016\/S2213-2600(21)00357-X","article-title":"Safety, reactogenicity, and immunogenicity of homologous and heterologous prime-boost immunisation with ChAdOx1 nCoV-19 and BNT162b2: a prospective cohort study","volume":"9","author":"Hillus","year":"2021","journal-title":"Lancet Respir Med"},{"key":"10.1016\/j.eururo.2026.01.012_b0045","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2022.1062210","article-title":"In-depth analysis of T cell immunity and antibody responses in heterologous prime-boost-boost vaccine regimens against SARS-CoV-2 and Omicron variant","volume":"13","author":"Heinen","year":"2022","journal-title":"Front Immunol"}],"container-title":["European Urology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0302283826000187?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0302283826000187?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,5,27]],"date-time":"2026-05-27T21:33:55Z","timestamp":1779917635000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0302283826000187"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,6]]},"references-count":9,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2026,6]]}},"alternative-id":["S0302283826000187"],"URL":"https:\/\/doi.org\/10.1016\/j.eururo.2026.01.012","relation":{},"ISSN":["0302-2838"],"issn-type":[{"value":"0302-2838","type":"print"}],"subject":[],"published":{"date-parts":[[2026,6]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Reply to the Harry Herr\u2019s Letter to the Editor re: Oscar Buisan, Pol Servian, Sonia Pedre\u00f1o-Lopez, et al. A Novel Heterologous Prime-boost Strategy Using RUTI Vaccine to Improve the Bacillus Calmette-Gu\u00e9rin Response in Non\u2013muscle-invasive Bladder Cancer Patients: Phase 1 RUTIVAC-1 Trial. Eur Urol. 2026;89:114\u2013120","name":"articletitle","label":"Article Title"},{"value":"European Urology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.eururo.2026.01.012","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"simple-article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 European Association of Urology. Published by Elsevier B.V. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}]}}